GSK Appeals Against NICE Decision To Deny Women Advanced Breast Cancer Treatment, Tyverb(R) (Lapatinib), UK

News — By on March 31, 2009 at 5:00 am

GlaxoSmithKline (GSK) confirmed that it is to appeal against the decision by NICE to deny NHS funding for Tyverb® (lapatinib), a treatment for an aggressive form of advanced breast cancer (ErbB2-positive).1 If successful the appeal will enable the NHS to offer a similar level of access to lapatinib as other EU countries.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback